Tiered Pricing - When a drug works better in some patients than others : IC Fireside Chats - Episode 14
Not all patients benefit equally. So what happens when a drug performs better in one subpopulation than another? Denmark’s SMA pricing model shows how tiered approaches can make pricing fair — aligning with outcomes and satisfying payer expectations. In this episode, we discuss how different evidence sets, real-world performance, and evolving patient stratification are reshaping price-per-value thinking.
Covered:
Denmark’s model for Spinal Muscular Atrophy (SMA)
The problem of uniform pricing across uneven efficacy
Designing contracting mechanisms that flex with data
Disclaimer: This presentation is for educational and informational purposes only, and is not intended as legal or policy advice. This presentation is based on non-confidential intelligence. Views expressed by the speakers are personal opinions and should not be attributed to anyone else. No part of this presentation may be reproduced for commercial purposes without the express permission of Verpora.
Never miss an episode
Receive a single email each week with a direct link to the latest IC Fireside Chat— no spam, just the latest episode, straight to your inbox.
Watch Next
